Ask the Expert: Is CBD oil safe and effective?
As part of our 'Ask the Expert' series, in partnership with Bon Secours St. Francis, 7NEWS spoke with a family medicine physician about CBD oil and whether it's safe and effective.
CBD oil is a product made from cannabidiol found in the cannabis plant, the same plant that produces marijuana, but doctors say it will not get you high.
'Unlike THC, which is tetrahydrocannabinol, a psychoactive compound in cannabis, CBD is non-psychoactive, meaning it does not cause a high sensation,' said Dr. Ryan Paulson.
Family medicine physician Dr. Ryan Paulson said once CBD is extracted from the cannabis plant, it is usually diluted with a carrier oil such as coconut oil or hempseed oil before being used in most commercial products.
He says doctors may recommend it for a variety of ailments.
'Common conditions where CBD oil can be recommended include chronic pain, anxiety, stress, sleep disorders, epilepsy or seizure disorders, inflammatory or autoimmune conditions such as Crohn's disease, ulcerative colitis, and skin conditions such as acne, eczema, or psoriasis,' said Dr. Ryan Paulson.
Generally, Dr. Paulson says CBD oil is safe for most people when used appropriately, but it's not recommended for everyone.
'There are definitely individuals who should not be utilizing CBD oil or should be using it with great caution… it can interact with certain medications or underlying health conditions. 'We strongly urge that we avoid use with pregnant or breastfeeding women, as there is limited research on the safety of CBD during pregnancy and breastfeeding; in children under the age of 18; people with liver issues; and those on certain medications such as warfarin, antidepressants, and benzodiazepines,' said Dr. Ryan Paulson.
Dr. Paulson says research on CBD oil is still evolving, and interactions with other treatments can vary. Therefore, consult your doctor before using these products.
'Your doctor can provide personalized guidance on proper dosage, potential interactions with other medications, and the best CBD products for your needs. That can also help you avoid any risk and ensure your overall treatment plan is effective and safe,' said Dr. Ryan Paulson.
In some cases, a doctor may prescribe CBD oil as part of their treatment plan.
'Particularly for certain medical conditions where there's strong evidence for its effectiveness,' said Dr. Ryan Paulson.
If you plan to purchase CBD oil over the counter, Dr. Paulson advises, ensure it's legitimate.
'To ensure you are purchasing a legitimate and safe CBD oil, you always want to look for third-party lab testing. Check the source and quality of the hemp and avoid brands that make unrealistic claims,' said Dr. Ryan Paulson.
To submit a health topic for our 'Ask the Expert' series, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Alabama CBD Customers: SUNMED Stores Are Open and Thriving
Sunmed™ | Your CBD Store® welcomes Alabama CBD customers! BIRMINGHAM, Ala., Aug. 1, 2025 /PRNewswire/ -- Your Alabama Sunmed™ | Your CBD Store® locations are open for business and carrying a full inventory of compliant, clinically proven and high-quality premium hemp and CBD full and broad-spectrum products. In appreciation of its customers' continued support, participating SUNMED stores across Alabama are offering FREE Wellness Gummy ($60 value). Promo Code: VIPAL25* Sunmed always strives to offer consumers wellness and therapeutic products that meet the highest standards with respect to quality, consumer safety and satisfaction. Recently enacted regulatory changes in Alabama had little or no impact with respect to Sunmed's CBD and hemp products. Sunmed welcomes reasonable regulations that guarantee consumer's access to Sunmed's wide variety of wellness goods and provide Sunmed small business store owners with the opportunity to continue to serve the community. Across Alabama please visit any of Sunmed | Your CBD Store Locations – Sunmed CBD. Offer valid at participating stores while products last. Additional restrictions apply. Void where prohibited, this offer cannot be combined with other offers. Limit 1 per household. Contact Patrick ShatzerSunmed l Your CBD Storecustomersupport@ About Sunmed™ | Your CBD Store® Sunmed | Your CBD Store, an affiliate of Sunflora, Inc., is the largest hemp retailer in the United States and the exclusive home of award-winning, hemp-derived Sunmed products. With 260+ nationwide locations across 39 states, the brand offers a premium in-store customer experience with access to 150+ nonpharmaceutical wellness formulas, including clinically proven sleep gummies, pain relief topicals, USDA-organic oil tinctures, and CBD for pets. Through in-store education, community involvement, and groundbreaking clinical research, Sunmed strives to empower modern wellness and enhance people's lives with natural science-backed products. Learn more at View original content to download multimedia: SOURCE Sunmed Sign in to access your portfolio
Associated Press
2 days ago
- Associated Press
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ('Artelo' or the 'Company') (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that it has received written scientific advice from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on the nonclinical development and first-in-human (FIH) clinical study plans for ART12.11, a novel cocrystal of Cannabidiol (CBD) and Tetramethylpyrazine (TMP). The MHRA agreed that reliance on the substantial body of historic nonclinical and clinical evidence for CBD, alongside legacy data for TMP, provides a scientifically justified basis for a streamlined clinical trial application (CTA)-enabling nonclinical development plan of the cocrystal combination to support the proposed FIH study, with clear guidance for achieving the agreed-upon FIH study design for ART12.11. The agency also affirmed that the proposed first-in-human (FIH) study design—a single-dose, multi-formulation crossover study—was methodologically sound for characterizing ART12.11's pharmacokinetic profile. Importantly, the MHRA offered constructive and specific guidance for completing the data package supporting the agreed-upon Phase 1 trial. Additionally, the agency proposed that ART12.11 may be a candidate for the Innovative Licensing and Access Pathway (ILAP). ILAP offers a unique opportunity to accelerate the development and patient access of promising new therapies through early and sustained collaboration with the MHRA, National Health Service, and health technology assessment bodies. Given ART12.11's novel mechanism and potential to address unmet needs in anxiety and depression, Artelo believes the program aligns well with ILAP's criteria and will evaluate a formal application to enter the pathway in the coming months. 'It's gratifying to receive this positive feedback and actionable recommendations from the MHRA, which provides a clear path forward as we prepare to initiate clinical studies with ART12.11,' said Dr. Andrew Yates, Chief Scientific Officer at Artelo. 'The recommendation to explore ILAP reinforces the proposition of ART12.11 as a novel drug with the potential to transform the treatment landscape for anxiety and depression.' Multiple nonclinical studies with ART12.11 have shown its promising profile compared to an antidepressant or CBD alone. The Company recently announced positive preclinical results in a depression model comparing ART12.11 with sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), where Artelo's patented CBD:TMP cocrystal demonstrated efficacy on par with sertraline and showed superior cognitive restoration compared to the leading SSRI. Additionally, in a rodent model of stress-induced anxiety and depression, where ART12.11 was compared to CBD dosed at 300% the amount of CBD contained in the oral tablet of ART12.11, the CBD:TMP cocrystal demonstrated efficacy where CBD alone did not. 'The clear regulatory assurance from the regulatory authority in the UK is expected to reduce expenses for our ART12.11 program,' added Gregory Gorgas, President & CEO at Artelo. 'We are especially pleased with the potential for an accelerated development strategy which could greatly accelerate our progress with ART12.11 and could provide for a longer period of market exclusivity as our patents are valid in 20 countries through the end of 2038. Over the next few months we look forward to finalizing our preparations to enter the clinic with ART12.11 early next year.' About ART12.11 ART12.11 is Artelo's wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Greatly enhanced pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile in a solid dosage form may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The U.S. issued composition of matter patent for ART12.11 is enforceable until December 10, 2038, and has now been granted or validated in 19 additional countries. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and Twitter: @ArteloBio. Forward Looking Statements Investor Relations Contact: Crescendo Communications, LLC Tel: 212-671-1020 Email: [email protected]
Yahoo
3 days ago
- Yahoo
Pizza restaurant serves marijuana-tainted food to unwitting customers
Health authorities say at least 85 people, including eight children, suffered accidental marijuana intoxication after eating pizza, sandwiches and garlic bread from a Wisconsin restaurant. Seven of them were rushed to the local hospital with symptoms ranging from dizziness to anxiety. None of them knew they were consuming pot, and investigators, after checking for carbon monoxide exposure, tracked down the source to an unexpected culprit. Authorities with the Centers for Disease Control and Prevention say the problems began when cooks at Famous Yeti's Pizza in a suburb of Madison, Wisconsin, ran out of canola oil last October. Instead of buying more oil, the restaurant workers grabbed cooking oil from a shared commissary area also used by a company that makes marijuana edibles, officials said. "The owner initially thought the oil was plain canola oil but later realized it might have been infused with THC," federal health officials concluded. Marijuana is illegal in Wisconsin, but the edibles company was extracting and concentrating the delta-9 THC compound from hemp, investigators said. Hemp is a low-THC version of marijuana, and thus legal in Wisconsin, even though both marijuana and hemp come from cannabis plants. "Regulations regarding practices such as standard, clear labeling and locked storage for ingredients containing THC might decrease the risk for unintentional THC exposure at licensed food businesses," the CDC concluded. Other recent mix-ups The Famous Yetis incident is among the latest examples of people potentially consuming intoxicating products sold as something else. On July 29, the FDA announced a recall by the California-based High Noon seltzer company after it discovered workers had inadvertently packaged alcoholic seltzer in energy drink cans. Last year, the parents of a two-year-old said workers at a Japanese restaurant accidentally served their toddler cooking wine mislabeled as apple juice. Critics of legal marijuana have long argued that manufacturers deliberately blur the lines with pot-infused products resembling normal cookies or candies, and many states that have legalized marijuana have strict rules intended to prevent such mixups. Emergency-room doctors have reported a significant increase in the number of patients they've treated as marijuana legalization has spread across the country, but acknowledge alcohol still drives far more emergency hospitalizations and injuries. The CDC says more than 2,100 Americans die annually from alcohol poisoning, and about 178,000 people nationally die as a result of excessive alcohol use. This article originally appeared on USA TODAY: Pizza joint: Wisconsin restaurant accidentally served pot-laced food Solve the daily Crossword
